Bydureon exenatide once weekly regulatory update

The Scottish Medicines Consortium recommended the restricted use of once-weekly Bydureon exenatide on the National Health Service (NHS) in Scotland only as a third-line treatment option for Type II diabetes. According to the consortium, the economic case for Bydureon as a second-line treatment option in combination with metformin has not been made. Bydureon is approved in the EU to treat Type II diabetes in combination with metformin, a sulphonylurea or a thiazolidinedione; metformin plus a sulphonylurea; or metformin plus thiazolidinedione. ...